## Guide A3P Scientifique & Technique





VOL.No 2 // June 2018

## Coordinator

Pierre DEVAUX, Contamination Control Expert, UPS CONSULTANTS

### **Contributors**

Margaux ARTHUS, Continuous Improvement Manager, GIFRER
Thierry BESNARD, Toxicological Expert, LABORATOIRE LTB
Sophie BOURGOIS, Cleaning Validation Expert, ASPEN
Ludovic DEMOOR, Production Manager – Filling Unit, LFB
Marilyne DOUEZ, Cleaning Process Engineer, NOVO NORDISK
Sandrine DUCLOS, Cleaning Validation Technical Expert, COPHACLEAN
Françoise DURAND, Scientific Manager, ANIOS

Guillaume GARREAU, Senior Cleaning Validation Engineer, GALDERMA / GSK CONSUMER HEALTHCARE

Isabelle GONZALEZ, Validation Manager, TEOXANE

Solenn JANVIER, Laboratory Manager, SERVIER

Christine LENS, President, KEYBIO

Etienne MICHEL, Global quality/Cleaning expert, GSK VACCINES

Stéphane MONESTIER, Packaging and process support manager, FERRING

Marie-Véronique MUNEREL, QA Manager, VIRBAC

Jean-Baptiste NOIROT COSSON, Manufacturing technical support supervisor, MERCK

Julie RACAUD, Qualification Validation Manager, AGUETTANT

Thomas ROHAUT, Cleaning Validation Adviser, AKTEHOM

Emilie SOLLIER, Cleaning Process and Validation Expert, SANOFI PASTEUR

Lauriane ZUCHUAT, Process and Cleaning Validation QA, VIFOR PHARMA

## **Table of Contents**

Foreword	
Definitions Acronyms	
§10.1  "Cleaning validation should be performed in order to confirm the effectiveness of any cleaning procedure for all product contact equipment."  "Simulating agents may be used with appropriate scientific justification."	10
"Where similar types of equipment are grouped together, a justification of the specific equipment selected for cleaning validation is expected."	11
§ 10.2  "A visual check for cleanliness is an important part of the acceptance criteria for cleaning validation. It is not generally acceptable for this criterion alone to be u  "Repeated cleaning and retesting until acceptable residue results are obtained is not considered an acceptable approach."	sed." 12
§10.3	
"It is recognized that a cleaning validation programme may take some time to be completed"	15
"Validation with verification after each batch may be required for some products, e.g. investigational medicinal products"  "There should be sufficient data from the verification to support a conclusion that the equipment is clean and available for further use"	16
	10
§10.4  "Validation should consider the level of automation in the cleaning process."	17
"Where an automatic process is used, the specified normal operating range of the utilities and equipment should be validated."	18
§10.5	
"For all cleaning processes an assessment should be performed to determine the variable factors which influence cleaning effectiveness and performance, e.g.,	operators, th
level of detail in procedures such as rinsing times etc."  "If variable factors have been identified, the worst case situation should be used as the basis for cleaning validation studies."	18
"If variable factors have been identified, the worst case situation should be used as the basis for cleaning validation studies."	19
§10.6	
"Limits for the carryover of product residues should be based on a toxicological evaluation. The justification for the selected limits should be documented in a ris which includes all the supporting references. Limits should be established for the removal of any cleaning agent used. Acceptance criteria should consider	
cumulative effect of multiple items of equipment in the process equipment train."	20
1. "Therapeutic macromolecules and peptides are known to degrade and denature when exposed to extreme pH and/or heat, and may become phan	macological
inactives. A toxicological evaluation may therefore not be applicable in these circumstances."  2. "If it is not feasible to test for specific product residues, other representative parameters may be selected, e.g. total organic carbon (TOC) and conductivi	tv" 20
	ty20
§10.7  "The risk presented by microbial and endotoxin contamination should be considered during the development of cleaning validation protocols."	98
	20
§ 10.8  "The influence of the time between manufacture and cleaning and the time between cleaning and use should be taken into account to define the maximum dirty and clean hold times for the cleaning process."	29
§10.9	
"Where campaign manufacture is carried out, the impact on the ease of cleaning at the end of the campaign should be considered and the maximum length of (in time and/or number of batches) should be the basis for cleaning validation exercises."	a campaign
§10.10	
"Where a worst case product approach is used as a cleaning validation model, a scientific rationale should be provided for the selection of the worst case produ	
"and the impact of new products to the assessed site" "Criteria for determining the worst case may include solubility, cleanability, toxicity and potency."	34
§10.11 "Cleaning validation protocols should specify or reference the locations to be sampled, the rationale for the selection of these locations and	
define the acceptance criteria."	36
§10.12	
"Sampling should be carried out by swabbing and/or rinsing or by other means depending on the production equipment. The sampling materials and methods	od should no
influence the result. Recovery should be shown to be possible from all product contact materials sampled in the equipment with all the sampling methods used.	"37
§10.13	
"The cleaning procedure should be performed an appropriate number of times based on a risk assessment and meet the acceptance criteria in order to prove tha	
method is validated."	39
§ 10.14	
"Where a cleaning process is ineffective or is not appropriate for some equipment, dedicated equipment or other appropriate measures should be used for each product as indicated in chapters 3 and 5 of EudraLex, Volume 4, Part I. as transcribed into national law by decision of the	
Head of the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM)."	40
§ 10.15	
"Where manual cleaning of equipment is performed, it is especially important that the effectiveness of the manual process should be confirmed at a justified fre	quency"41
, , , , , , , , , , , , , , , , , , , ,	,
Bibliographic References	49
Annex 1/ Example of a risk analysis to define Worst Case equipment	
Annex 2/Clean and dry condition	46
Annex 3/ Example of Worst Case Product Matrix	48

#### **Foreword**

With the implementation of the new Annex 15 of the Eudralex European GMP guidelines volume IV in October 2015, the cleaning validation process took on an entirely different dimension in the context of our production activities. Eight paragraphs were added to Chapter 10 which is dedicated to this subject and this represents a major regulatory change!

These modifications have raised many questions on our industrial sites with respect to the practical application of all these paragraphs.

Let us take the PDE value (Permitted Daily Exposure) for example: "How do we find the source data to calculate this value? Should it be based solely on toxicological studies? How is this value calculated? Is there an obligation to call on a Expert CV toxicologist to calculate this PDE?

All attention is focused on this PDE value and its practical application described in the EMA guideline of 2014 "Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities".

Nevertheless it is important to mention the following point: beyond the PDE, for which for the following draft document, published by the EMA in January 2017, specified when calculation of this value is obligatory or not (Questions and answers on implementation of risk based prevention of cross contamination in production and Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities). It remains the case that all the other points in Chapter 10 are to be applied and incorporated in your cleaning validation strategies.

The 15 paragraphs of Chapter 10 of Annex 15 are complex to interpret. They should serve as a reference for several production areas (sterile and non-sterile medicinal products in the human health sector, biotechnologies, veterinary industry) and can serve as reference for other industrial sectors such as cosmetics and medical devices. In these conditions, it seemed to us opportune to create a working group on the subject, the most comprehensive group possible, composed of producers and suppliers, with a maximum number of industrial sectors represented. In this way the GIC A3P VN came into existence on September 26, 2016.

The objective of this GIC was to provide you with a guide to the interpretation and practical application of the points in Chapter 10 of Annex 15 of the European GMP guidelines. Through this work and our highly informative discussions, we have been able to assess all the difficulties encountered in our organizations regarding the definition and setting up of cleaning validation strategies. This is why we wished to develop a guide for you that is as pragmatic as possible, which does not claim to be the only solution but the most complete working tool possible to help you define a cleaning validation strategy that takes account of the specific features of each of your organizations.

We thank the A3P Association for having believed in us and for having allowed us to carry out this work under excellent conditions.

# §10.1: "Cleaning validation should be performed in order to confirm the effectiveness of any cleaning procedure for all product contact equipment."

Cleaning validation should check the reproducibility and effectiveness of cleaning processes. It therefore ensures the robustness of the cleaning process.

Cleaning validation is dependent:

- on the products (finished product, raw materials, intermediate products of production),
- · on the equipment,
- · on the processes (manufacturing process and cleaning process),
- on the environment.




Figure 1: Scope of the cleaning validation

The scope of cleaning validation should include the surfaces of equipment which present a contamination risk for the following product.

Above and beyond the notion of product contact, the following points must be taken into account to define the scope of the validation:

- The risk of contamination by a product residue (Cross Contamination): transfer of an ingredient used in the production of product A to product B.
- Risk of microbiological contamination: risk of proliferation of microorganisms (for example during DHT) and the presence/generation of endotoxins.
- The risk of contamination by cleaning and/or disinfection agents: risque de retrouver des composants utilisés dans le procédé de nettoyage.
- Risk of contamination by the environment (during CHT): Risk of contamination by the environment (during CHT):

Elements which present an identified risk of contamination, in direct or indirect contact with the product, should be included in the scope of cleaning process validation.